Lasting remission of a Muckle-Wells syndrome with CIAS-1 mutation using half-dose anakinra.
Gerard
Stéphanie
S
le Goff
Benoît
B
Maugars
Yves
Y
Berthelot
Jean-Marie
JM
Malard
Olivier
O
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D002352:Carrier Proteins / Q000235:genetics* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006319:Hearing Loss, Sensorineural; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D000071199:NLR Family, Pyrin Domain-Containing 3 Protein; D010146:Pain / Q000188:drug therapy; D010147:Pain Measurement; D012074:Remission Induction; D013577:Syndrome; D016896:Treatment Outcome; D014581:Urticaria / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism
D018501:Antirheumatic Agents; D002352:Carrier Proteins; D053590:Interleukin 1 Receptor Antagonist Protein; D000071199:NLR Family, Pyrin Domain-Containing 3 Protein; C453881:NLRP3 protein, human